ArticleInternational urology and nephrology2026
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Meet-URO score, incorporating IMDC classification, neutrophil-to-lymphocyte ratio (NLR), and bone metastases, was developed in European patients receiving second-line nivolumab; its applicability to Asian populations, particularly in real-world first-line immune checkpoint inhibitor (ICI)-based combination cohorts, remains uncertain. We externally validated the Meet-URO score in Japanese patients with metastatic renal cell carcinoma (mRCC) receiving first-line ICI-based combinations.
methodsThis retrospective multicenter study enrolled mRCC patients treated with first-line ICI-based combinations at five Japanese institutions, stratified into five Meet-URO groups; overall survival (OS) was the primary endpoint, evaluated using Harrell's C-index.
resultsBetween 2018 and 2022, 152 patients were screened and 151 patients were enrolled. Treatment regimens included nivolumab plus ipilimumab (64.9%), pembrolizumab plus axitinib (27.8%), avelumab plus axitinib (4.0%), and nivolumab plus cabozantinib (3.3%). The median potential follow-up was 16.1 months (95%CI 13.2-19.3), estimated by the reverse Kaplan-Meier method. The Meet-URO score significantly stratified OS (p = 0.0017), cancer-specific survival (p = 0.0022), and progression-free survival (p = 0.0428). The 24-month OS rates were 100%, 94.8%, 55.0%, 54.9%, and 39.7% for Groups 1-5, respectively. The C-index for OS was 0.731 (95%CI 0.655-0.807), numerically higher than but not statistically significantly different from IMDC classification (0.702; bootstrap difference 0.029, 95%CI - 0.082 to 0.134, p = 0.298). Overall response rate and disease control rate differed significantly across groups, whereas grade ≥ 3 adverse events did not.
conclusionThis study provides an Asian validation of the Meet-URO score, supporting its prognostic utility in this Japanese multicenter cohort receiving first-line ICI-based combinations. Treatment imbalance across Meet-URO groups and a short follow-up warrant cautious interpretation and further validation.
Indexed as
Identifiers
42012775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.